Axsome Therapeutics AXSM EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's EBITDA?
- Axsome Therapeutics (AXSM) reported EBITDA of -$61.67M in Q1 2026.
- How has Axsome Therapeutics's EBITDA changed year-over-year?
- Axsome Therapeutics's EBITDA decreased by 11.6% year-over-year, from -$55.26M to -$61.67M.
- What is the long-term trend for Axsome Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EBITDA has grown at a 6.4% compound annual growth rate (CAGR), from -$124.63M to -$159.88M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.